Precision BioSciences IPO

3/27/2019

IPO

$126,400,000

Proceeds will be used as follows: approximately $7.0 to $9.0 million to initiate and complete a Phase 1/2a clinical trial for our CD19 CAR T cell product candidate; approximately $50.0 to $52.0 million to advance and expand the development of our other CAR T cell product candidates and allogeneic CAR T immunotherapy platform, including to submit an IND for each of our CD20, BCMA and CLL-1 CAR T cell product candidates; approximately $18.0 to $20.0 million to advance and expand the preclinical development of our in vivo gene correction platform, including early discovery efforts, chemistry, manufacturing and controls, or CMC, and IND-enabling studies; approximately $12.0 to $14.0 million to fund the build-out of our planned cGMP-compliant manufacturing facility; and the remainder to fund new and ongoing research and development activities, to fund the portion of expenses we are responsible for with respect to the development of our food platform and for working capital and other general

Publicly-held

Biopharmaceutical

302 East Pettigrew St. Dibrell Building A-100
Durham, NC 27701
USA

The Precision BioSciences (Nasdaq: DTIL) mission is to translate the world's most powerful genome editing technology into greatly needed products throughout the life sciences.